Background: In the absence of randomized data comparing osimertinib to platinum-based doublet chemotherapy (PBDC) in patients (pts) with metastatic epidermal growth factor receptor (EGFRm) T790M non-small cell lung cancer (NSCLC) who have progressed after EGFR-TKI, an adjusted indirect comparison can offer a robust estimate of treatment effect.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile